Categories AlphaGraphs, Earnings, Health Care
Infographic: Highlights of Moderna’s (MRNA) Q4 2023 earnings results
Biotechnology company Moderna, Inc. (NASDAQ: MRNA) reported a sharp decline in revenues and earnings for the fourth quarter of 2023.
Net income fell to $217 million or $0.55 per share in the December quarter from $1.47 billion or $3.61 per share in the same period of fiscal 2022.
The bottom line was negatively impacted by a 45% fall in revenues to $2.81 billion. There was a 43% drop in product revenues. The management reaffirmed its full-year 2024 product sales guidance at approximately $4 billion.
“We look forward to the anticipated approvals of our RSV vaccine beginning in the first half of the year. With multiple upcoming Phase 3 data readouts in 2024, we remain focused on commercial execution and continued investment in our pipeline with financial discipline,” said Moderna’s CEO Stéphane Bancel.
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
CL Earnings: Key quarterly highlights from Colgate-Palmolive’s Q2 2024 financial results
Colgate-Palmolive Company (NYSE: CL) reported its second quarter 2024 earnings results today. Net sales increased 4.9% year-over-year to $5 billion. Organic sales increased 9%. Net income attributable to Colgate-Palmolive Company was $731
Key takeaways from Visa’s Q3 2024 earnings report
Credit card behemoth Visa, Inc. (NYSE: V) this week reported mixed results for the June quarter, with earnings matching expectations and sales slightly missing the view. Both numbers grew in
Southwest Airlines (LUV): A look at the airline’s performance in Q2 2024
Shares of Southwest Airlines Co. (NYSE: LUV) were up over 6% on Thursday after the company beat earnings estimates for the second quarter of 2024. The stock has gained 4%